Processa Pharmaceuticals, Inc. (PCSA)
NASDAQ:PCSA
Want to see PCSA full AI Analyst Report?
Top Page
Processa Pharmaceuticals
(NASDAQ:PCSA)
Select Model
Select Model
Rating:43Neutral
Price Target:
$2.50
▲(1983.33% Upside)
Action:Reiterated
Date:06/12/26
PCSA scores low primarily due to weak financial performance driven by sustained losses and substantial ongoing cash burn alongside a materially reduced equity base. Technicals also weigh on the score as the stock trades below major moving averages with negative MACD. Valuation provides limited support because earnings are negative and no dividend yield is indicated.
Positive Factors
Low leverage / no debt
Zero reported debt materially reduces interest and refinancing risk, giving the company structural financial flexibility. For a clinical-stage biotech, low leverage preserves optionality to raise targeted capital or partner deals without immediate debt service constraints, aiding long-term program execution.
Negative Factors
High and persistent cash burn
Sustained operating and free cash outflows near -$15M TTM create ongoing funding needs and force reliance on external capital or partnerships. Over the medium term this increases dilution risk, constrains discretionary R&D expansion, and can delay programs if financing windows tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / no debt
Zero reported debt materially reduces interest and refinancing risk, giving the company structural financial flexibility. For a clinical-stage biotech, low leverage preserves optionality to raise targeted capital or partner deals without immediate debt service constraints, aiding long-term program execution.
Read all positive factors
Processa Pharmaceuticals (PCSA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.52M
Dividend YieldN/A
Average Volume (3M)58.30K
Price to Earnings (P/E)―
Beta (1Y)0.27
Revenue GrowthN/A
EPS Growth86.07%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-10.66
Shares Outstanding2,750,173
10 Day Avg. Volume62,463
30 Day Avg. Volume58,304
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market Cap0.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-13.65K
Enterprise Value/Ebitda-0.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6
Revenue Forecast (FY)$10.01M
Processa Pharmaceuticals Business Overview & Revenue Model
Company Description
Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The co...
How the Company Makes Money
null...
Processa Pharmaceuticals Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
38
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -301.00 | 0.00 | 0.00 | 0.00 | -874.01K | 0.00 |
| EBITDA | -14.11M | -13.56M | -11.85M | -11.12M | -26.64M | -10.78M |
| Net Income | -14.11M | -13.56M | -11.85M | -11.12M | -27.42M | -11.43M |
Balance Sheet | ||||||
| Total Assets | 4.52M | 7.81M | 3.23M | 5.79M | 8.62M | 26.46M |
| Cash, Cash Equivalents and Short-Term Investments | 1.69M | 5.54M | 1.19M | 4.71M | 6.50M | 16.50M |
| Total Debt | 0.00 | 0.00 | 73.51K | 150.55K | 229.45K | 78.46K |
| Total Liabilities | 1.98M | 2.24M | 1.53M | 797.48K | 1.15M | 978.40K |
| Stockholders Equity | 2.54M | 5.58M | 1.70M | 4.99M | 7.47M | 25.49M |
Cash Flow | ||||||
| Free Cash Flow | -12.25M | -11.39M | -11.25M | -8.07M | -9.61M | -8.72M |
| Operating Cash Flow | -12.25M | -11.39M | -11.25M | -8.06M | -9.61M | -8.72M |
| Investing Cash Flow | -1.35M | -850.00K | -3.24K | -2.78K | 0.00 | 0.00 |
| Financing Cash Flow | 12.39M | 16.58M | 7.73M | 6.27M | -388.84K | 9.80M |
Processa Pharmaceuticals Technical Analysis
Negative
0.12
Price Trends
2.72
Negative
2.66
Negative
4.36
Negative
Market Momentum
-0.12
Positive
45.50
Neutral
19.63
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PCSA, the sentiment is Negative. The current price of 0.12 is below the 20-day moving average (MA) of 2.58, below the 50-day MA of 2.72, and below the 200-day MA of 4.36, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 45.50 is Neutral, neither overbought nor oversold. The STOCH value of 19.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PCSA.
Processa Pharmaceuticals Risk Analysis
Processa Pharmaceuticals disclosed 41 risk factors in its most recent earnings report. Processa Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Processa Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $18.14M | -1.31 | -66.69% | ― | -45.52% | -94.82% | |
45 Neutral | $13.93M | -1.58 | -94.94% | ― | ― | 53.06% | |
43 Neutral | $6.52M | -0.44 | -281.30% | ― | ― | 86.07% | |
42 Neutral | $7.90M | -0.04 | -154.50% | ― | ― | -92.20% | |
41 Neutral | $6.30M | -753.96 | ― | ― | ― | ― | |
41 Neutral | $6.39M | -0.40 | -246.04% | ― | ― | 54.48% |
* Healthcare Sector Average
PCSA
Processa Pharmaceuticals
2.37
-6.24
-72.47%
CANF
Can-Fite BioPharma
2.85
-18.75
-86.81%
SNGX
Soligenix
0.43
-1.41
-76.58%
LPCN
Lipocine
2.20
-0.96
-30.38%
COCP
Cocrystal Pharma
1.01
-0.53
-34.42%
PHGE
BiomX
0.71
-7.27
-91.14%
Processa Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Processa Pharmaceuticals Announces Transition of Chief Development Officer
Neutral
Apr 30, 2026
On April 30, 2026, Processa Pharmaceuticals approved a planned transition toward retirement for Dr. Sian Bigora, its Chief Development and Regulatory Officer. Effective May 1, 2026, she moved from a full-time executive officer role to a part-time ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.